home > > summer 2019 > the changing face of clinical data

The Changing Face of Clinical Data

Data collection and analysis have always been central to the development of new clinical interventions such as drug treatments, diagnostics, and medical devices. While clinical data have always been collected and analysed, in recent years emerging methods and technologies for collection, analysing and utilising data, as well as the sheer quantity of data collected have been changing, driven by innovation and an evolving drug development landscape.

Clinical data can take many forms, but are essentially any information collected about an individual over the course of their admission and treatment in a medical setting. These data can range from their medical record information (such as age and medical history), the clinical interventions they undergo (such as blood tests, drugs prescribed, and surgical procedures), and the resulting outcomes following an intervention. These measures form the basis of any clinical trial that seeks to establish the efficacy or safety of a novel drug treatment, medical device, or diagnostic.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
About the author

Aiden Flynn is the Founder of Exploristics and has more than 20 years’ experience in drug discovery and clinical development. After seven years as a lecturer at University College London, UK, Aiden spent 10 years at GlaxoSmithKline as a Director of statistical support for biomarker studies across R&D. In recent years, he has worked closely with the FDA and EMEA to develop tools and guidelines that support the use of biomarkers in clinical studies. Since founding Exploristics in 2009, Aiden has attracted over 50% of the world’s top pharma companies as clients, as well as many biotechnology, device, and diagnostic companies.

Print this page
Send to a friend
Privacy statement
News and Press Releases

Teva launches AJOVY for the treatment of migraine with the YpsoMate autoinjector from Ypsomed

Burgdorf – Teva Pharmaceutical Industries Ltd. (Teva), a global leader in generic medicines with innovative treatments in select areas, including central nervous system, pain and respiratory, launches its drug product AJOVY® in the pre-filled YpsoMate 2.25 autoinjector from Ypsomed. AJOVY® is used for the preventive treatment of migraine in adults. The collaboration with Teva marks the first commercial market entry of Ypsomed’s larger 2.25 ml autoinjector YpsoMate 2.25.
More info >>

White Papers

Advantages of Quantitative NMR for the Determination of Relative Response Factors

Novatia, LLC

Quantitative NMR (qNMR) is a technique that is being applied broadly and at an increasing rate in the field of pharmaceutical analysis (1). This white paper highlights the advantages of using qNMR to determine Relative Response Factors (RRFs) for pharmaceutical impurities detectable by HPLC. A single determination of RRFs using qNMR allows for simple and accurate quantitation of impurities which eliminates the need for preparation, qualification, and storage of reference standards. An example is presented here, which demonstrates quantitation of known impurities that have variable responses to UV-VIS detection, thereby providing a more accurate assessment of impurity levels than UV-VIS response alone.
More info >>

Industry Events

World Vaccine Congress Washington

27-29 September 2020, Walter E Washington Convention Center, Washington, US

The World Vaccine Congress is an award-winning series of conferences and exhibitions that have grown to become the largest and most established vaccine meeting of its kind across the globe. Our credibility is show through the prestigious scientific advisory board that spend months of hard work creating a new and topical agenda, year on year.
More info >>



©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement